<DOC>
	<DOCNO>NCT01935128</DOCNO>
	<brief_summary>The purpose study evaluate whether conversion everolimus ( Zortress® ) , allow elimination reduction calcineurin inhibitor , reduce nephrotoxicity ( measure increase creatinine clearance ) lengthen overall graft ( kidney transplant ) survival ( measure 2-3 year graft survival ) .</brief_summary>
	<brief_title>Evaluation Calcineurin-inhibitor Reduction With Conversion 2 Months Everolimus/Reduced Tacrolimus Renal Transplant Recipients Following Campath® Induction</brief_title>
	<detailed_description>The purpose study evaluate whether conversion everolimus ( Zortress® ) , allow elimination reduction calcineurin inhibitor , reduce nephrotoxicity ( measure increase creatinine clearance ) lengthen overall graft ( kidney transplant ) survival ( measure 2-3 year graft survival ) . Among bad long-term effect chronic immunosuppression nephrotoxicity ( toxic kidney cell ) calcineurin inhibitor myriad complication steroid . This protocol evaluate elimination reduction calcineurin inhibitor protocol already successfully eliminate long-term use steroid . A considerable need remain safer therapeutic agent inhibit T-cell activation ( white blood cell attack foreign cell part immune response ) via calcineurin independent reduced-dose mechanism action .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Male female renal allograft recipient least 18 year old . Patients give write informed consent participate study . If consent express writing , must formally document witnessed , ideally via independent trusted witness . Patient receive kidney transplant decease living unrelated/related donor . Recipient kidney allograft cold ischemia time ( CIT ) &lt; 36 hour . Female patient must negative pregnancy test prior study enrollment . Patients calcineurin inhibitor ( ) ( CNI ) ( tacrolimus myfortic® ) without steroid maintenance follow Campath® induction . Patients acceptable allograft function define serum creatinine &lt; 2.5 mg/dL ( 250 μmol/L ) actual estimate glomerular filtration rate ( eGFR ) ( Modification diet renal disease equation 4 , MDRD4 ) ≥ 30 mL/min/1.73m2 ( without renal replacement therapy ) . No evidence rejection since time transplantation . Recipient ABO incompatible allograft positive crossmatch . Patient human immunodeficiency virus ( HIV ) positive . Patient receive allograft Hepatitis B surface Antigen ( HBsAg ) Hepatitis C Virus ( HCV ) positive donor . HBsAg and/or HCV positive patient evidence elevate liver function test ( LFTs ) ( Alanine transaminase/Aspartate transaminase [ ALT/AST ] level ≥ 2.5 time upper limit normal [ ULN ] ) . Viral serology result obtain within 6 month prior randomization acceptable . Patient severe restrictive ( total lung capacity [ TLC ] &lt; 50 % ) obstructive pulmonary ( forced expiratory volume one second [ FEV1 ] &lt; 50 ) disorder . Patient severe allergy require acute ( within 4 week baseline ) chronic treatment would prevent patient potential exposure everolimus , hypersensitivity drug similar everolimus ( e.g . macrolides ) . Patients know hypersensitivity/contraindication immunosuppressant class , excipients . Patient severe hypercholesterolemia ( &gt; 300 mg/dL ) hypertriglyceridemia ( &gt; 400 mg/dL ) control despite lipid lower therapy . Patient white blood cell ( WBC ) count ≤ 1,000 /mm3 ( absolute neutrophil count [ ANC ] &lt; 500 ) platelet count ≤ 50,000 /mm3 . History malignancy organ system , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . ( Localized basal cell carcinoma skin time , small ( less 4 cm ) lowgrade renal cancer , bladder cancer , treated prostate cancer evidence disease 2 year allowable ) Graft loss . Patient renal replacement therapy . Patient experience biopsy proven rejection . Proteinuria &gt; 1 g/day ( calculated urinary proteintocreatinine ratio ) . Patients recurrence Focal Segmental Glomerulosclerosis ( FSGS ) . Patient current severe systemic infection accord investigator judgment require continue therapy would interfere objective study . Patients ongoing wound heal problem , clinically significant infection require continue therapy severe surgical complication opinion investigator . Presence intractable immunosuppressant complication side effect . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive serum human chorionic gonadotrophin laboratory test ( &gt; 5 mIU/mL ) Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Transplant</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Steroid Avoidance</keyword>
	<keyword>Calcineurin Avoidance</keyword>
	<keyword>Mammalian Target Rapamycin ( mTOR )</keyword>
	<keyword>Kidney</keyword>
</DOC>